SCHEMBL22970445

SCHEMBL22970445

Cc1ccn(CC(O)CC(F)(F)F)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBLB Q13191 1/20 0.37
NOS1 P29475 1/20 0.35
GAA P10253 2/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
CNR2 P34972 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR3 P22607 1/20 0.32
MAPT P10636 2/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
ATM Q13315 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
AKR1C3 P42330 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669048 0.80 NOS1 (0.39) CBLBNOS1GAAMAPTRAB9A
SCHEMBL18214837 0.75 NOS1 (0.41) CBLBNOS1GAALMNAMAPT
SCHEMBL25619472 0.75 NOS1 (0.41) CBLBNOS1GAALMNAMAPT
SCHEMBL31030377 0.75 HPGD (0.38) NOS1GAALMNATSHRMAPT
SCHEMBL21266850 0.74 JAK2 (0.34) JAK2JAK1TYK2JAK3LMNA
SCHEMBL19504430 0.73 GAA (0.41) CBLBNOS1GAAMAPTRAB9A
SCHEMBL10049910 0.73 GAA (0.37) CBLBNOS1GAAMAPTRAB9A
SCHEMBL29300697 0.72 GAA (0.36) CBLBNOS1GAALMNAMAPT
SCHEMBL6972157 0.71 GAA (0.38) CBLBNOS1GAALMNAMAPT
SCHEMBL23985340 0.70 DRD2 (0.39) CBLBNOS1GAAMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286248-B2 Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) 2022-03-29 US disclosed
US-20210040070-A1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040070-A1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR FGFR1, FGFR2, FGFR3 CBLB 4272/4885NOS1 4099/4885GAA 1140/4885
US-11286248-B2 Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor FGFR1, FGFR2, FGFR3 CBLB 4272/4885NOS1 4099/4885GAA 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.